2.56 USD
-0.23
8.24%
At close Feb 14, 4:00 PM EST
After hours
2.58
+0.02
0.78%
1 day
-8.24%
5 days
-12.33%
1 month
-12.93%
3 months
-31.00%
6 months
-42.34%
Year to date
-28.89%
1 year
21.90%
5 years
98.45%
10 years
-19.24%
 

About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Employees: 141

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

198% more call options, than puts

Call options by funds: $15.4M | Put options by funds: $5.18M

70% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 27

42% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 60

17% more capital invested

Capital invested by funds: $1.98B [Q2] → $2.32B (+$330M) [Q3]

7% more funds holding

Funds holding: 238 [Q2] → 255 (+17) [Q3]

5.88% more ownership

Funds ownership: 78.74% [Q2] → 84.62% (+5.88%) [Q3]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
173%
upside
Avg. target
$8
213%
upside
High target
$9
252%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Gil Blum
17% 1-year accuracy
28 / 168 met price target
173%upside
$7
Buy
Maintained
13 Jan 2025
HC Wainwright & Co.
Emily Bodnar
20% 1-year accuracy
31 / 155 met price target
252%upside
$9
Buy
Reiterated
10 Dec 2024

Financial journalist opinion

Based on 3 articles about GERN published over the past 30 days

Positive
Seeking Alpha
1 week ago
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
GERN's Rytelo, approved in mid-2024, shows promising initial sales, with Q3'24 net revenues at $28.2M, and preliminary Q4'24 net revenues of $45M-$46M. Despite some market exclusivity concerns, GERN still has many years of sales ahead unencumbered by generic competition. EU approval of Rytelo for lower-risk myelodysplastic syndromes seems likely in H1'25, providing a near-term catalyst beyond updates on sales.
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Neutral
Business Wire
1 week ago
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. E.
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Neutral
Business Wire
3 weeks ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,000 shares of its common stock, consisting of stock options to purchase an aggregate of 208,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 104,000 shares of common stock, to three newly hired employees as an inducement material to their acceptance of employm.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
1 month ago
Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Geron Corporation's RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is awaiting European Medicines Agency approval as well, which might help to boost sales. Geron reported $28.2 million in the first full quarter of sales of RYTELO, with projections of $45-$46 million set for Q4 2024. Geron is conducting a Phase 3 study for RYTELO targeting JAK inhibitor relapsed/refractory Myelofibrosis patients, with interim results expected by early 2026 and final results early 2027.
Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Positive
Zacks Investment Research
1 month ago
Geron Stock Rallies More Than 60% in a Year: Here's Why
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
Geron Stock Rallies More Than 60% in a Year: Here's Why
Neutral
Business Wire
1 month ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 18, 2024, at an exercise price $3.77 per share, which is equal to the closing price of Geron common stock o.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
2 months ago
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myel.
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Neutral
Business Wire
2 months ago
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced new analyses presented at the 66th American Society of Hematology (ASH) Annual Meeting from the IMerge clinical trial in patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia suggesting clinical activity of first-in-class telomerase inhibitor RYTELO™ (imetelstat).
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
Neutral
Business Wire
2 months ago
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced results from an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety results from the dose escalation Part 1 suggest the tolerability of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, in.
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
Neutral
Business Wire
2 months ago
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET. A webcast of the fireside chat will be available through the Investors and Media section of Geron's website under Events following the presentation. The.
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Charts implemented using Lightweight Charts™